Home Cart 0 Sign in  
X

[ CAS No. 1878-66-6 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 1878-66-6
Chemical Structure| 1878-66-6
Chemical Structure| 1878-66-6
Structure of 1878-66-6 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 1878-66-6 ]

Related Doc. of [ 1878-66-6 ]

Alternatived Products of [ 1878-66-6 ]

Product Details of [ 1878-66-6 ]

CAS No. :1878-66-6 MDL No. :MFCD00004344
Formula : C8H7ClO2 Boiling Point : -
Linear Structure Formula :- InChI Key :CDPKJZJVTHSESZ-UHFFFAOYSA-N
M.W : 170.59 Pubchem ID :15880
Synonyms :
Chemical Name :2-(4-Chlorophenyl)acetic acid

Calculated chemistry of [ 1878-66-6 ]

Physicochemical Properties

Num. heavy atoms : 11
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.12
Num. rotatable bonds : 2
Num. H-bond acceptors : 2.0
Num. H-bond donors : 1.0
Molar Refractivity : 43.0
TPSA : 37.3 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.84 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.48
Log Po/w (XLOGP3) : 2.12
Log Po/w (WLOGP) : 1.97
Log Po/w (MLOGP) : 2.25
Log Po/w (SILICOS-IT) : 2.18
Consensus Log Po/w : 2.0

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.56

Water Solubility

Log S (ESOL) : -2.5
Solubility : 0.533 mg/ml ; 0.00313 mol/l
Class : Soluble
Log S (Ali) : -2.53
Solubility : 0.498 mg/ml ; 0.00292 mol/l
Class : Soluble
Log S (SILICOS-IT) : -2.79
Solubility : 0.279 mg/ml ; 0.00164 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.2

Safety of [ 1878-66-6 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P271-P280-P302+P352+P312-P304+P340+P312-P362+P364-P501 UN#:N/A
Hazard Statements:H312-H332 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 1878-66-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 1878-66-6 ]
  • Downstream synthetic route of [ 1878-66-6 ]

[ 1878-66-6 ] Synthesis Path-Upstream   1~19

  • 1
  • [ 1878-66-6 ]
  • [ 85-44-9 ]
  • [ 20526-97-0 ]
Reference: [1] Synthetic Communications, 2013, vol. 43, # 8, p. 1127 - 1137
[2] Pharmazie, 1958, vol. 13, p. 619,621
[3] Patent: US2820738, 1954, ,
[4] Patent: DE947473, 1954, ,
[5] Journal of Organic Chemistry, 1980, vol. 45, # 18, p. 3618 - 3620
[6] Journal of Medicinal Chemistry, 1993, vol. 36, # 25, p. 4052 - 4060
[7] Bioorganic and Medicinal Chemistry Letters, 2003, vol. 13, # 16, p. 2769 - 2772
[8] Organic Letters, 2009, vol. 11, # 20, p. 4712 - 4715
[9] Patent: DE947473, 1954, ,
  • 2
  • [ 1878-66-6 ]
  • [ 95-54-5 ]
  • [ 5468-66-6 ]
YieldReaction ConditionsOperation in experiment
95%
Stage #1: at 110℃;
Stage #2: at 120℃; for 1 h;
(101.8 mmol) of 4-chlorophenylacetic acid and 0.37 mg (0.46 mmol) of sodium benzoate were added to a 50 ml reaction flask equipped with a mechanical stirrer, thermometer, water separator and reflux condenser. The temperature was increased to 110 C, and 10 g (92.5 mmol) of o-phenylenediamine was added thereto, and the temperature was raised to 120 ° C for 1 hour. The reaction process and reaction endpoint were monitored by TLC (Developing solvent: ethyl acetate: petroleum ether = 1: 1, Rf = 0.41). The reactants were neutralized with 5 wtpercent Na0H solution and stirred until the pH was 7. 0 to 8.5; filter, washed with water to neutral crude, with ethanol - water mixed solvent recrystallization (volume ratio of 1: 2 ~ 1: 3), filtration, drying in pure 21 3g, the
85% With boric acid In 5,5-dimethyl-1,3-cyclohexadiene for 16 h; Reflux General procedure: To a stirred solution of benzene-1,2-diamine 1 (1.85 mmol)in xylenes (10 mL) were added carboxylic acid 2 (2.77 mmol)and boric acid (0.185 mmol). The resulting solution wasrefluxed for 16 h. After cooling to room temperature, the reactionwas concentrated under reduced pressure and diluted withEtOAc (50 mL). The organic phase was washed with saturatedNaHCO3 solution (2 50 mL), dried over anhydrous Na2SO4and then concentrated under reduced pressure. The residuewas purified by silica gel flash column chromatography (elutingwith 10–15percent Ethyl acetate in hexanes) to afford the title compounds3a–y and 5.6.2.5
2-(4-Chlorobenzyl)-1H-benzo[d]imidazole (3e)
Yield 85percent; Off white solid; mp 191-194 °C; IR (KBr) 2850, 2751, 1512, 1451, 1410, 1241, 1181, 1025, 812, 749 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 12.26 (br s, 1H), 7.52 (br s, 1H), 7.31-7.45 (m, 5H), 7.07-7.16 (m, 2H), 4.17 (s, 2H); 13C NMR (100 MHz, DMSO-d6) δ 153.2, 136.7, 134.5, 131.3, 130.8, 128.5, 121.8, 121.1, 118.3, 111.0, 34.1; HRMS calcd for C14H11ClN2 m/z 242.0625, found 242.0621.
Reference: [1] Patent: CN103483266, 2016, B, . Location in patent: Paragraph 0054; 0055; 0056
[2] Bioorganic and Medicinal Chemistry, 2016, vol. 24, # 8, p. 1872 - 1878
[3] Journal of the American Chemical Society, 1954, vol. 76, p. 1883,1886
[4] Pharmazie, 2003, vol. 58, # 5, p. 303 - 307
  • 3
  • [ 1878-66-6 ]
  • [ 53242-88-9 ]
Reference: [1] Archiv der Pharmazie, 1988, vol. 321, # 4, p. 205 - 208
[2] Synthetic Communications, 2013, vol. 43, # 8, p. 1127 - 1137
[3] Molecules, 2013, vol. 18, # 3, p. 3479 - 3501
[4] Patent: WO2007/122156, 2007, A1,
  • 4
  • [ 1878-66-6 ]
  • [ 25026-34-0 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2007, vol. 17, # 22, p. 6160 - 6163
[2] Bioorganic and Medicinal Chemistry Letters, 2007, vol. 17, # 10, p. 2899 - 2903
[3] Bioorganic and Medicinal Chemistry, 2002, vol. 10, # 8, p. 2779 - 2793
[4] Synthetic Communications, 2008, vol. 38, # 16, p. 2845 - 2856
[5] Biochemische Zeitschrift, 1910, vol. 27, p. 102
[6] Bulletin de la Societe Chimique de France, 1968, p. 4898 - 4901
[7] Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1972, p. 1276 - 1281
[8] Archiv der Pharmazie, 1988, vol. 321, # 5, p. 265 - 272
[9] Journal of Medicinal Chemistry, 1991, vol. 34, # 1, p. 397 - 403
[10] Journal of Medicinal Chemistry, 1991, vol. 34, # 2, p. 752 - 757
[11] Archiv der Pharmazie, 1991, vol. 324, # 5, p. 283 - 286
[12] Journal of the American Chemical Society, 1983, vol. 105, # 7, p. 1861 - 1868
[13] Journal of the American Chemical Society, 1984, vol. 106, # 11, p. 3344 - 3353
[14] Journal of Medicinal Chemistry, 1993, vol. 36, # 16, p. 2279 - 2291
[15] Journal of Medicinal Chemistry, 1992, vol. 35, # 21, p. 3745 - 3754
[16] Indian Journal of Chemistry - Section B Organic Chemistry Including Medicinal Chemistry, 1990, vol. 29, # 11, p. 1034 - 1040
[17] Chemische Berichte, 1989, vol. 122, p. 331 - 336
[18] Journal of Medicinal Chemistry, 1994, vol. 37, # 11, p. 1704 - 1711
[19] Journal of Heterocyclic Chemistry, 1995, vol. 32, # 6, p. 1767 - 1773
[20] Journal of Medicinal Chemistry, 1996, vol. 39, # 7, p. 1509 - 1513
[21] Journal of Mass Spectrometry, 1996, vol. 31, # 7, p. 761 - 766
[22] Chemical and Pharmaceutical Bulletin, 1997, vol. 45, # 12, p. 1984 - 1993
[23] Journal of Organic Chemistry, 1999, vol. 64, # 8, p. 2814 - 2820
[24] Bioorganic and Medicinal Chemistry Letters, 2000, vol. 10, # 15, p. 1723 - 1727
[25] Farmaco, 2000, vol. 55, # 5, p. 397 - 405
[26] Farmaco, 2000, vol. 55, # 6-7, p. 469 - 476
[27] Heterocycles, 2002, vol. 57, # 1, p. 39 - 46
[28] Monatshefte fur Chemie, 2003, vol. 134, # 3, p. 403 - 409
[29] Bioorganic and Medicinal Chemistry Letters, 2003, vol. 13, # 5, p. 821 - 823
[30] Journal of the American Chemical Society, 1948, vol. 70, p. 500
[31] Scientia Pharmaceutica, 2001, vol. 69, # 4, p. 329 - 350
[32] Synthetic Communications, 2003, vol. 33, # 13, p. 2215 - 2227
[33] Archiv der Pharmazie, 2003, vol. 336, # 11, p. 514 - 522
[34] Arzneimittel-Forschung/Drug Research, 2003, vol. 53, # 4, p. 266 - 271
[35] Journal of Medicinal Chemistry, 2004, vol. 47, # 6, p. 1434 - 1447
[36] Archiv der Pharmazie, 2004, vol. 337, # 7, p. 402 - 410
[37] Bioorganic and Medicinal Chemistry, 2007, vol. 15, # 5, p. 2032 - 2044
[38] Bioorganic and Medicinal Chemistry, 2003, vol. 11, # 23, p. 5155 - 5170
[39] Carbohydrate Research, 2004, vol. 339, # 11, p. 1873 - 1887
[40] Bioorganic and Medicinal Chemistry, 2005, vol. 13, # 2, p. 443 - 448
[41] Bioorganic and Medicinal Chemistry, 2006, vol. 14, # 7, p. 2209 - 2224
[42] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2006, vol. 45, # 4, p. 1080 - 1085
[43] Journal of Medicinal Chemistry, 2006, vol. 49, # 12, p. 3563 - 3580
[44] Journal of Medicinal Chemistry, 2006, vol. 49, # 20, p. 6104 - 6110
[45] Journal of Medicinal Chemistry, 2007, vol. 50, # 1, p. 40 - 64
[46] Journal of Medicinal Chemistry, 2001, vol. 44, # 25, p. 4468 - 4474
[47] Chemistry of Heterocyclic Compounds, 2006, vol. 42, # 7, p. 901 - 906
[48] Patent: US4254048, 1981, A,
[49] Patent: US4544670, 1985, A,
[50] Patent: US4803280, 1989, A,
[51] Patent: US4851526, 1989, A,
[52] Patent: US4035499, 1977, A,
[53] Patent: US4196294, 1980, A,
[54] Patent: US4206240, 1980, A,
[55] Patent: WO2007/20381, 2007, A2, . Location in patent: Page/Page column 27
[56] Patent: WO2008/92873, 2008, A1, . Location in patent: Page/Page column 28-29
[57] European Journal of Medicinal Chemistry, 2008, vol. 43, # 9, p. 2004 - 2010
[58] Patent: WO2004/112774, 2004, A1, . Location in patent: Page/Page column 35; 40-41
[59] Organic and Biomolecular Chemistry, 2009, vol. 7, # 17, p. 3561 - 3571
[60] Journal of Medicinal Chemistry, 2009, vol. 52, # 10, p. 3366 - 3376
[61] Organic Process Research and Development, 2010, vol. 14, # 1, p. 225 - 228
[62] Tetrahedron Letters, 2010, vol. 51, # 21, p. 2888 - 2891
[63] ACS Medicinal Chemistry Letters, 2010, vol. 1, # 4, p. 145 - 149
[64] Angewandte Chemie - International Edition, 2011, vol. 50, # 1, p. 314 - 318
[65] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 20, p. 6116 - 6121
[66] European Journal of Medicinal Chemistry, 2012, vol. 48, p. 231 - 243
[67] Organic and Biomolecular Chemistry, 2012, vol. 10, # 8, p. 1598 - 1601
[68] Organic Letters, 2012, vol. 14, # 8, p. 2154 - 2157
[69] Bioorganic and Medicinal Chemistry, 2012, vol. 20, # 12, p. 3915 - 3924
[70] Chinese Chemical Letters, 2012, vol. 23, # 11, p. 1233 - 1236,4
[71] Medicinal Chemistry Research, 2012, vol. 21, # 11, p. 3818 - 3825
[72] Bioorganic and Medicinal Chemistry, 2013, vol. 21, # 11, p. 2886 - 2894
[73] Patent: WO2013/104831, 2013, A1, . Location in patent: Page/Page column 9; 10
[74] Journal of Agricultural and Food Chemistry, 2013, vol. 61, # 28, p. 6792 - 6798
[75] Patent: WO2013/167996, 2013, A1, . Location in patent: Paragraph 0096; 0097
[76] Chemistry - A European Journal, 2013, vol. 19, # 46, p. 15565 - 15571
[77] Organic and Biomolecular Chemistry, 2013, vol. 11, # 48, p. 8375 - 8386
[78] European Journal of Medicinal Chemistry, 2014, vol. 73, p. 73 - 82
[79] European Journal of Medicinal Chemistry, 2014, vol. 75, p. 438 - 447
[80] Tetrahedron, 2014, vol. 70, # 11, p. 1975 - 1983
[81] Organic Syntheses, 2012, vol. 89, p. 44 - 54
[82] Journal of Medicinal Chemistry, 2014, vol. 57, # 6, p. 2755 - 2772
[83] RSC Advances, 2013, vol. 3, # 48, p. 26230 - 26240
[84] Journal of the American Chemical Society, 2014, vol. 136, # 39, p. 13602 - 13605
[85] Tetrahedron Letters, 2015, vol. 56, # 12, p. 1575 - 1580
[86] Letters in Drug Design and Discovery, 2015, vol. 12, # 3, p. 190 - 205
[87] RSC Advances, 2015, vol. 5, # 88, p. 72373 - 72386
[88] Angewandte Chemie - International Edition, 2015, vol. 54, # 50, p. 15051 - 15054[89] Angew. Chem., 2015, vol. 54-127, # 50, p. 15265 - 15268,4
[90] Chemical Biology and Drug Design, 2016, vol. 87, # 5, p. 673 - 679
[91] Tetrahedron, 2016, vol. 72, # 39, p. 5886 - 5897
[92] Patent: US2016/213640, 2016, A1, . Location in patent: Paragraph 0793
[93] Patent: WO2016/112088, 2016, A1, . Location in patent: Paragraph 0253
[94] Patent: WO2016/137010, 2016, A1, . Location in patent: Paragraph 0111
[95] European Journal of Medicinal Chemistry, 2017, vol. 127, p. 187 - 199
[96] European Journal of Organic Chemistry, 2017, vol. 2017, # 20, p. 2866 - 2870
[97] Journal of Organic Chemistry, 2017, vol. 82, # 14, p. 7332 - 7345
[98] Journal of Medicinal Chemistry, 2017, vol. 60, # 14, p. 6205 - 6219
[99] Patent: CN107200712, 2017, A, . Location in patent: Paragraph 0122; 0124; 0125
[100] Patent: WO2017/192844, 2017, A1, . Location in patent: Paragraph 00187
[101] Journal of Medicinal Chemistry, 2017, vol. 60, # 23, p. 9769 - 9789
[102] European Journal of Medicinal Chemistry, 2018, vol. 149, p. 45 - 55
[103] Journal of Medicinal Chemistry, 2018, vol. 61, # 8, p. 3565 - 3581
[104] Tetrahedron Letters, 2018, vol. 59, # 30, p. 2913 - 2916
  • 5
  • [ 1878-66-6 ]
  • [ 79-37-8 ]
  • [ 25026-34-0 ]
Reference: [1] Patent: US4724263, 1988, A,
  • 6
  • [ 1878-66-6 ]
  • [ 37777-68-7 ]
Reference: [1] Patent: WO2013/131408, 2013, A1, . Location in patent: Page/Page column 66; 67
  • 7
  • [ 1878-66-6 ]
  • [ 5445-25-0 ]
Reference: [1] Bulletin de la Societe Chimique de France, 1956, p. 776,780, 781
  • 8
  • [ 1878-66-6 ]
  • [ 24091-92-7 ]
YieldReaction ConditionsOperation in experiment
37% With thionyl chloride; bromine In methanol Step A:
Preparation of methyl 2-bromo-2-(4-chlorophenyl)acetate
A mixture of 4-chlorophenylacetic acid (5.00 g, 29.3 mmol) and thionyl chloride (2.67 mL, 1.25 eq) were heated at reflux while bromine (1.51 mL, 1.0 eq) was added from a dropping funnel over 15 minutes.
The reaction mixture was heated at reflux 19.5 hours, and then cooled to room temperature.
Methanol (30 mL, 25 eq) was then added slowly, as an exotherm and violent bubbling resulted.
The reaction mixture was then concentrated in vacuo.
The residue was partitioned between water and ether and the aqueous phase was then extracted twice with ether.
The combined ether portions were washed with 5percent NaHSO3, dried (MgSO4), filtered, and concentrated in vacuo.
The residue was purified on a silica gel flash chromatography column (170*45 mm) eluted with 15percent ethyl acetate/hexane to yield 2.89 g (37percent) of the title compound.
1 H NMR (300 MHz, CDCl3, ppm): δ3.8 (s, 3H), 5.35 (s, 1H), 7.2-7.3 (d, 2H), 7.45-7.55 (d, 2H). EI-MS: m/e 262, 264, 266 (M+, 10:13:3 ratio).
Reference: [1] Tetrahedron, 2002, vol. 58, # 51, p. 10113 - 10126
[2] Journal of Medicinal Chemistry, 1993, vol. 36, # 23, p. 3738 - 3742
[3] Patent: US6613802, 2003, B1,
[4] Patent: US2003/220399, 2003, A1,
[5] Patent: US6624194, 2003, B1,
[6] Patent: US5240938, 1993, A,
[7] Patent: US6262118, 2001, B1,
[8] Advanced Synthesis and Catalysis, 2015, vol. 357, # 11, p. 2479 - 2484
  • 9
  • [ 1878-66-6 ]
  • [ 6529-53-9 ]
Reference: [1] Organic Letters, 2012, vol. 14, # 18, p. 4842 - 4845,4
[2] Bioorganic and Medicinal Chemistry Letters, 2006, vol. 16, # 18, p. 4752 - 4756
[3] Tetrahedron Asymmetry, 1998, vol. 9, # 15, p. 2725 - 2737
[4] Journal of Medicinal Chemistry, 1981, vol. 24, # 4, p. 404 - 408
[5] Journal of Organic Chemistry, 1964, vol. 29, # 8, p. 2109 - 2116
[6] Journal of the American Chemical Society, 1977, vol. 99, # 9, p. 3059 - 3067
[7] Beilstein Journal of Organic Chemistry, 2011, vol. 7, p. 386 - 393
[8] Synthesis (Germany), 2013, vol. 45, # 23, p. 3233 - 3238
[9] Patent: CN106478506, 2017, A,
  • 10
  • [ 1878-66-6 ]
  • [ 75-29-6 ]
  • [ 2012-74-0 ]
YieldReaction ConditionsOperation in experiment
91% With potassium hydroxide In 5,5-dimethyl-1,3-cyclohexadiene; water EXAMPLE 22
In the xylene dispersion of fine potassium hydroxide having particle diameter of less than 100μ obtained by the process of Example 1, 26 g. (0.33 mole) of isopropyl chloride was charged, and then a solution of 37.5 g. (0.22 mole) of 4-chlorophenylacetic acid in 50 ml. of xylene was added dropwise during about 10 minutes and then, the reaction was continued at 70°-80° C. for 50 minutes.
After the reaction, the reaction mixture was poured into 300 ml. of water and the organic layer was separated and concentrated to distil off xylene and the product was distilled under a reduced pressure to obtain 43 g. (yield of 91percent) of α-isopropyl-4-chlorophenylacetic acid (m.p. 88°-89° C.).
Reference: [1] Patent: US4307034, 1981, A,
  • 11
  • [ 1878-66-6 ]
  • [ 5188-07-8 ]
  • [ 16188-55-9 ]
YieldReaction ConditionsOperation in experiment
79.3% With copper(I) bromide In N,N-dimethyl-formamide at 130℃; for 24 h; Inert atmosphere 10g of 4-bromophenylacetic acid was added to 20 mL of DMF, 20 mL of DMF was added, 5.0 g of sodium methanethiol was added,Copper 0.5g, nitrogen replacement, stirring to increase the reaction temperature to 130 ° C under nitrogen protection, stirring reaction 24 hours, cooling reactionAnd the remainder were the same as in Example 1 of the present invention, and the yield was 79.3percent.; Taking 4- bromobenzene acetic acid 10g in 100 ml in three-mouth bottle, by adding DMF20mL, adding a thiol sodium 5.0g, adding cuprous bromide 0.1g, after the replacement of nitrogen, to improving the reaction temperature under stirring 130 °C, under the protection of nitrogen stirring for 4 hours, cooling the reaction liquid, by adding 40percent NaOH5mL, stirring 10 minutes. Cooling the reaction liquid, by adding ethyl acetate 25 ml extraction two, by adding ethyl acetate in 50 ml, by adding 10percent dilute sulfuric acid adjusted to pH 2-4, collecting ethyl acetate, ethyl acetate with water 10 ml after washing, distillation of the ethyl acetate to 20 ml left and right, by adding hexane 20 ml, raise the reaction temperature to reflux, after to be solid entirely dissolved, a slow cooling to room temperature, filtered, scaled to obtain yellowish crystalline, to obtain a target product after drying 6.38g, yield 76.1percent.
Reference: [1] Patent: CN105646306, 2016, A, . Location in patent: Paragraph 0011
  • 12
  • [ 1878-66-6 ]
  • [ 19677-37-3 ]
Reference: [1] Canadian Journal of Chemistry, 1994, vol. 72, # 11, p. 2312 - 2317
[2] Patent: WO2005/123724, 2005, A1,
  • 13
  • [ 1878-66-6 ]
  • [ 130754-19-7 ]
Reference: [1] Journal of Fluorine Chemistry, 1990, vol. 49, # 1, p. 115 - 126
[2] Journal of Fluorine Chemistry, 1990, vol. 49, # 1, p. 115 - 126
  • 14
  • [ 373-91-1 ]
  • [ 75581-01-0 ]
  • [ 1878-66-6 ]
  • [ 74590-69-5 ]
Reference: [1] Patent: US4215044, 1980, A,
  • 15
  • [ 1878-66-6 ]
  • [ 74590-69-5 ]
Reference: [1] Journal of the American Chemical Society, 1980, vol. 102, # 14, p. 4845 - 4846
  • 16
  • [ 1878-66-6 ]
  • [ 85-44-9 ]
  • [ 53242-76-5 ]
YieldReaction ConditionsOperation in experiment
80%
Stage #1: at 240 - 250℃; for 3 h;
Stage #2: With water; sodium hydroxide In water for 4 h; Reflux
Proportionion of p-chlorophenylacetic acid, phthalic anhydride and freshly melted sodium acetate in a reaction kettle,Rapidly heated to about 250 ° C,Stirring reaction at 240-250 ° C for 3 hours, the water produced during the reaction is discharged from the tail pipe;The reaction mixture is then placed in an open heat-resistant container while hot.Cool with stirring and add cold absolute ethanol.Heating to dissolve the solid as much as possible, cooling and filtering.Wash with absolute ethanol,filter,dry.The obtained solid is added to a solution of sodium hydroxide and water, stirred under reflux for 4 hours, cooled, diluted with water, acidified to pH 2-3 with 20percent hydrochloric acid, and stirred, cooled, and precipitated as a solid oil. , filtered, dried to obtain a crude product, the crude product was dissolved in acetone, the insoluble matter was filtered off, and acetone was evaporated.The residue was recrystallized from ethyl acetate.Get the product. MP 142-144 ° C, yield 80percent.
Reference: [1] Patent: CN108003005, 2018, A, . Location in patent: Paragraph 0010; 0011; 0012
  • 17
  • [ 1878-66-6 ]
  • [ 53242-76-5 ]
Reference: [1] Archiv der Pharmazie, 1988, vol. 321, # 4, p. 205 - 208
  • 18
  • [ 1878-66-6 ]
  • [ 270596-42-4 ]
Reference: [1] Patent: CN107501112, 2017, A,
  • 19
  • [ 1878-66-6 ]
  • [ 918516-27-5 ]
Reference: [1] Patent: WO2018/2415, 2018, A1,
[2] Patent: WO2018/2415, 2018, A1,
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 1878-66-6 ]

Aryls

Chemical Structure| 51719-65-4

[ 51719-65-4 ]

2-(3,5-Dichlorophenyl)acetic acid

Similarity: 0.95

Chemical Structure| 5807-30-7

[ 5807-30-7 ]

3,4-Dichlorophenylacetic acid

Similarity: 0.95

Chemical Structure| 2444-36-2

[ 2444-36-2 ]

2-Chlorophenylacetic acid

Similarity: 0.95

Chemical Structure| 4619-18-5

[ 4619-18-5 ]

4-(4-Chlorophenyl)butyric acid

Similarity: 0.93

Chemical Structure| 2019-34-3

[ 2019-34-3 ]

3-(4-Chlorophenyl)propanoic acid

Similarity: 0.93

Chlorides

Chemical Structure| 51719-65-4

[ 51719-65-4 ]

2-(3,5-Dichlorophenyl)acetic acid

Similarity: 0.95

Chemical Structure| 5807-30-7

[ 5807-30-7 ]

3,4-Dichlorophenylacetic acid

Similarity: 0.95

Chemical Structure| 2444-36-2

[ 2444-36-2 ]

2-Chlorophenylacetic acid

Similarity: 0.95

Chemical Structure| 4619-18-5

[ 4619-18-5 ]

4-(4-Chlorophenyl)butyric acid

Similarity: 0.93

Chemical Structure| 2019-34-3

[ 2019-34-3 ]

3-(4-Chlorophenyl)propanoic acid

Similarity: 0.93

Carboxylic Acids

Chemical Structure| 51719-65-4

[ 51719-65-4 ]

2-(3,5-Dichlorophenyl)acetic acid

Similarity: 0.95

Chemical Structure| 5807-30-7

[ 5807-30-7 ]

3,4-Dichlorophenylacetic acid

Similarity: 0.95

Chemical Structure| 2444-36-2

[ 2444-36-2 ]

2-Chlorophenylacetic acid

Similarity: 0.95

Chemical Structure| 4619-18-5

[ 4619-18-5 ]

4-(4-Chlorophenyl)butyric acid

Similarity: 0.93

Chemical Structure| 2019-34-3

[ 2019-34-3 ]

3-(4-Chlorophenyl)propanoic acid

Similarity: 0.93